CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson’s Disease
In recent years, the innovation of gene-editing tools such as the CRISPR/Cas9 system improves the translational gap of treatments mediated by gene therapy. The privileges of CRISPR/Cas9 such as working in living cells and organs candidate this technology for using in research and treatment of the central nervous system (CNS) disorders. Parkinson’s disease (PD) is a common, debilitating, neurodegenerative disorder which occurs due to loss of dopaminergic neurons and is associated with progressive motor dysfunction. Knowledge about the pathophysiological basis of PD has altered the classification system of PD, which manifests in familial and sporadic forms. The first genetic linkage studies in PD demonstrated the involvement of Synuclein alpha (SNCA) mutations and SNCA genomic duplications in the pathogenesis of PD familial forms. Subsequent studies have also insinuated mutations in leucine repeat kinase-2 (LRRK2), Parkin, PTEN-induced putative kinase 1 (PINK1), as well as DJ-1 causing familial forms of PD. This review will attempt to discuss the structure, function, and development in genome editing mediated by CRISP/Cas9 system. Further, it describes the genes involved in the pathogenesis of PD and the pertinent alterations to them. We will pursue this line by delineating the PD linkage studies in which CRISPR system was employed. Finally, we will discuss the pros and cons of CRISPR employment vis-à-vis the process of genome editing in PD patients’ iPSCs.
KeywordsParkinson disease Gene editing CRISPR-associated protein 9 Induced pluripotent stem cells Neuroinflammation
It is certified that no funding has been received for the preparation of this manuscript
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
As no human participants are involved in this study no informed consent had been obtained.
- Emamalizadeh B et al (2014) RIT2, a susceptibility gene for Parkinson’s disease in Iranian population. Neurobiol Aging 35(12):e27–e28. https://doi.org/10.1016/j.neurobiolaging.2014.07.013 CrossRefPubMedGoogle Scholar
- Gordon R, Anantharam V, Kanthasamy AG, Kanthasamy A (2012) Proteolytic activation of proapoptotic kinase protein kinase Cdelta by tumor necrosis factor alpha death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation 9:82. https://doi.org/10.1186/1742-2094-9-82 CrossRefPubMedPubMedCentralGoogle Scholar
- Grundemann J, Schlaudraff F, Haeckel O, Liss B (2008) Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson’s disease. Nucleic Acids Res 36:e38. https://doi.org/10.1093/nar/gkn084 CrossRefPubMedPubMedCentralGoogle Scholar
- Hanrott K, Murray TK, Orfali Z, Ward M, Finlay C, O’Neill MJ, Wonnacott S (2008) Differential activation of PKC delta in the substantia nigra of rats following striatal or nigral 6-hydroxydopamine lesions. Eur J Neurosci 27(5):1086–1096. https://doi.org/10.1111/j.1460-9568.2008.06097.x CrossRefPubMedGoogle Scholar
- Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S (2009) Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15(4):300–306. https://doi.org/10.1016/j.parkreldis.2008.07.010 CrossRefPubMedGoogle Scholar
- Qing X, Walter J, Jarazo J, Arias-Fuenzalida J, Hillje AL, Schwamborn JC (2017) CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and alpha-Synuclein modulation in dopaminergic neurons. Stem Cell Res 24:44–50. https://doi.org/10.1016/j.scr.2017.08.013 CrossRefPubMedGoogle Scholar
- Safari F, Tamaddon AM, Zarghami N, Abolmali S, Akbarzadeh A (2016) Polyelectrolyte complexes of hTERT siRNA and polyethyleneimine: effect of degree of PEG grafting on biological and cellular activity. Artif Cells Nanomed Biotechnol 44(6):1561–1568. https://doi.org/10.3109/21691401.2015.1064936 CrossRefPubMedGoogle Scholar
- Wang Y, Wang X, Li R, Yang ZF, Wang YZ, Gong XL, Wang XM (2013) A DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson’s disease-related genes in dopaminergic neurons. CNS Neurosci Ther 19(3):183–190. https://doi.org/10.1111/cns.12059 CrossRefPubMedPubMedCentralGoogle Scholar
- Zhang D, Kanthasamy A, Yang Y, Anantharam V, Kanthasamy A (2007) Protein kinase C delta negatively regulates tyrosine hydroxylase activity and dopamine synthesis by enhancing protein phosphatase-2A activity in dopaminergic neurons. J Neurosci 27(20):5349–5362. https://doi.org/10.1523/jneurosci.4107-06.2007 CrossRefPubMedPubMedCentralGoogle Scholar